ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DAWN Day One Biopharmaceuticals Inc

14.99
-0.20 (-1.32%)
Pre Market
Last Updated: 08:00:16
Delayed by 15 minutes

Period:

Draw Mode:

Volume 909
Bid Price 14.61
Ask Price 14.87
News -
Day High

Low
9.67

52 Week Range

High
17.85

Day Low
Company Name Stock Ticker Symbol Market Type
Day One Biopharmaceuticals Inc DAWN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.20 -1.32% 14.99 08:00:16
Open Price Low Price High Price Close Price Prev Close
15.19
Trades Volume Avg Volume 52 Week Range
25 909 - 9.67 - 17.85
Last Trade Time Type Quantity Stock Price Currency
08:00:23 1 $ 14.75 USD

Day One Biopharmaceuticals (DAWN) Options Flow Summary

Overall Flow

Bullish

Net Premium

226k

Calls / Puts

200.00%

Buys / Sells

12.50%

OTM / ITM

50.00%

Sweeps Ratio

0.00%

Day One Biopharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.33B 87.38M - 0 -188.92M -2.16 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Day One Biopharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DAWN Message Board. Create One! See More Posts on DAWN Message Board See More Message Board Posts

Historical DAWN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week14.8617.3914.4415.883,043,4520.130.87%
1 Month15.8917.3913.5715.451,334,447-0.90-5.66%
3 Months15.2717.8513.5515.42888,707-0.28-1.83%
6 Months10.2117.859.7614.28743,0954.7846.82%
1 Year11.8517.859.6713.49884,7683.1426.50%
3 Years25.0028.6995.4415.57663,232-10.01-40.04%
5 Years25.0028.6995.4415.57663,232-10.01-40.04%

Day One Biopharmaceuticals Description

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Your Recent History

Delayed Upgrade Clock